Future research directions for evaluating human genetic and cancer risk from environmental exposures

Environmental Health Perspectives

Volumn 104, Issue SUPPL. 3, 1996, Pages 503-510

  Albertini, Richard J ^a,b   Nicklas, Janice A ^a   O'Neill, J Patrick ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b GeneticToxicology Laboratory   (United States)

Author keywords

Biomarkers; Cancer; Environmental exposures; Genetic risk; Genetic susceptibility

Indexed keywords

BIOLOGICAL MONITORING; CANCER RISK; CONFERENCE PAPER; ENVIRONMENTAL EXPOSURE; GENETIC RISK; GENOTOXICITY; HUMAN; PRIORITY JOURNAL;

EID: 0029885484     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.96104s3503     Document Type: Conference Paper

References (85)

1. Albertini RJ, Robison SH. Human population monitoring. In: Genetic Toxicology (Li AP, Heflich RH, eds). Boca Raton:CRC Press, 1991:375-420.
2. Committee on Biological Markers of the National Research Council. Biological markers in environmental health research. Environ Health Perspect 74:3-9 (1987).
3. Lloyd DC, Purrott RJ, Reeder EJ. The incidence of unstable chromosome aberrations in peripheral blood lymphocytes from unirradiated and occupationally exposed people. Mutat Res 72:523-532 (1980).
4. Brewen JG, Preston RJ. The use of chromosome aberrations for predicting genetic hazard in man. In: Radiation Research. Biomedical, Chemical, and Physical Perspectives (Nygaard O, Adler H, Sinclair W, eds). New York:Academic Press, 1975;926-936.
5. Santella RM. Application of new techniques for the detection of carcinogen adducts to human population monitoring. Mutat Res 205:271-282 (1988).
6. Petera FP. The significance of DNA and protein adducts in human biomonitoring studies. Mutat Res 205:255-269 (1988).
7. Burkhart JG. Perspectives on molecular assays for measuring mutation in humans and rodents. Environ Mol Mutagen 25(Suppl 26):88-101 (1995).
8. Dipple A. DNA adducts of chemical carcinogens. Carcinogenesis 16:437-441 (1995).
9. Neumann HG. Analysis of hemoglobin as a dose monitor for alkylating and arylating agents. Arch Toxicol 56:1-6 (1984).
10. Ostermann-Golkar S, Ehrenberg L, Segerback D, Hallstrom I. Evaluation of genetic risks of alkylating agents. II. Haemoglobin as a dose monitor. Mutat Res 34:1-10 (1987).
11. Segerback D, Calleman CJ, Ehrenberg L, Lofroth G, Osterman-Golkar S. Evaluation of genetic risks of alkylating agents. IV. Quantitative determination of alkylated amino acids in haemoglobin as a measure of the dose after treatment of mice with methyl methanesulfonate. Mutat Res 49:71-82 (1978).
12. Calleman CJ. In vivo dosimetry by means of alkylated hemoglobin - a tool in the design of tests for genotoxic effects. In: Indicators of Genotoxic Exposure (Bridges BA, Butterworth BE, Weinstein IB, eds). Banbury Report 13. Cold Spring Harbor, NY:Cold Spring Harbor Laboratory, 1982;157-168.
13. Osterman-Golkar S, Christakoppoulos A, Zorcec V, Svensson K. Dosimetry of styrene 7,8-oxide in styrene- and styrene oxide-exposed mice and rats by quantification of haemoglobin adducts. Chem Biol Interact 95:79-87 (1995).
14. Keith G, Dirheimer G. Postlabeling: a sensitive method for studying DNA adducts and their role in carcinogenesis. Curr Opin Biotechnol 6:3-11 (1995).
15. Haugen A, Becker G, Benstad C, Vahakangas K, Trivers GE, Newman MJ, Harris CC. Determination of polycyclic aromatic hydrocarbons in the urine, benzo[a]pyrene diol epoxide-DNA adducts in lymphocyte DNA, and antibodies to the adducts in sera from coke oven workers exposed to measured amounts of polycyclic aromatic hydrocarbons in the work atmosphere. Cancer Res 46:4178-4183 (1986).
16. Groopman JD, Donahue JPR, Zhu J, Chen J, Wogan GN. Aflatoxin metabolism in humans: detection of metabolites and nucleic acid adducts in urine by affinity chromatography. Proc Nat Acad Sci USA 82:6492-6496 (1985).
17. Lee BM, Strickland PT. Antibodies to carcinogen-DNA adducts in mice chronically exposed to polycyclic aromatic hydrocarbons. Immunol Lett 36:117-123 (1993).
18. Harris CC, Vahakangas K, Newman MJ, Trivers GE, Shamsuddin A, Sinopoli N, Mann DL, Wright WE. Detection of benzo[a]pyrene diol epoxide-DNA adducts in peripheral blood lymphocytes and antibodies to the adducts in serum from coke oven workers. Proc Nat Acad Sci USA 82:6672-6676 (1985).
19. Vineis P, Bartsch H, Caporaso N, Harrington AM, Kadlubar FF, Landi MT, Malaveifle C, Shields PG, Skipper P, Talaska G, Tannenbaum SR. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 369:155-156 (1994).
20. Lin HJ, Han CY, Lin BK, Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. Am J Hum Genet 52:827-834 (1993).
21. Yu MC, Skipper PL, Taghizadeh K, Tannenbaum SR, Chan KK, Henderson BE, Ross RK. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black and Asian men in Los Angeles, California. J Natl Cancer Inst 86:712-716 (1994).
22. Kroemer HK, Eichelbaum M. It's in the genes, stupid. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 56:2285-2298 (1995).
23. Nebett DW, McKinnon. Cytochrome P450: evolution and functional diversity. Prog Liver Dis 12:63-97 (1994).
24. Wolf CR, Smith CA, Forman D. Metabolic polymorphisms in carcinogen metabolising enzymes and cancer susceptibility. Br Med Bull 50:718-731 (1994).
25. Kadlubar FF. Biochemical individuality and its implications for drug and carcinogen metabolism: recent insights from acetyltransferase and cytochrome P4501A2 phenotyping and genotyping in humans. Drug Metab Rev 26:37-46 (1994).
26. Ingelman-Sundberg M, Johansson I, Persson I, Oscarson M, Hu Y, Bertilsson L, Dahl ML, Sjoquist F. Genetic polymorphism of cytochrome P450. Functional consequences and possible relationship to disease and alcohol toxicity. EXS 71:197-207 (1994).
27. Lehmann AR. Xeroderma pigmentosum, Cockayne syndrome and ataxia-telangiectasia: disorders relating DNA repair to carcinogenesis. Cancer Surv 1:93-118 (1982).
28. Lehmann AR, Norris PG. DNA repair and cancer: speculations based on studies with xeroderma pigmentosum, Cockayne's syndrome and trichothiodystrophy. Carcinogenesis 10:1353-1356 (1989).
29. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH. Germ line p53 mutations in a familial syndrome of breast cancer, sarcoma, and other neoplasms. Science 250:1233-1238 (1990).
30. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, Ashkenazi M, Pecker I, Frydman M, Harnik R, Patanjali SR, Simmons A, Clines GA, Sartiel A, Gatti RA, Chessa L, Sanal O, Lavin MF, Jaspers NGL, Taylor AMR, Arlett CF, Miki T, Weissman SM, Lovett M, Collins FS, Shiloh Y. A single ataxia telangiectasia gene with a product similar to PL-3 kinase. Science 268:1749-1753 (1995).
31. Nicotera TM. Molecular and biochemical aspects of Bloom's syndrome. Cancer Genet Cytogenet 53:1-13 (1991).
32. Perera FP, Santella R. Carcinogenesis. In: Molecular Epidemiology: Principles and Practices (Schulte P, Perera FP, eds). New York: Academic Press, 1993;277-300.
33. Hoeijmakers JH. Human nucleotide excision repair syndromes: molecular clues to unexpected intricacies. Eur J Cancer Clin Oncol 30A:1912-1921 (1994).
34. Ponz de Leon M. Cancer-prone hereditary disease associated with abnormalities of DNA repair. Recent Results Cancer Res 136:322-331 (1994).
35. Taylor AM, McConville CM, Byrd PJ. Cancer and DNA processing disorders. Br Med Bull 50:708-717 (1994).
36. Kraemer KH, Levy DD, Parris CN, Gozukara EM, Moriwaki S, Adelberg S, Seidman MM. Xeroderma pigmentosum and related disorders: examining the linkage between defective DNA repair and cancer. J Invest Dermatol 103(Suppl 5):96S-101S (1994).
37. Lee W-H, Bookstein R, Hong F, Young L-J, Shew J-Y, Lee EY-HP. Human retinoblastoma gene: cloning, identification, and sequence. Science 235:1394-1399 (1987).
38. Nicolaides NC, Papadopoulos N, Liu B, Wei Y-F, Carter KC, Ruben SM, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM, Adams MD, Venter JC, Dunlop MG, Hamilton SR, Petersen GM, de la Chapelle A, Vogelstein B, Kinzler KW. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 371:75-80 (1994).
39. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Hen J, Parsons R, Peltomaki P, Sistonen P, Aaltonen LA, NystromLahti M, Guan X-Y, Zhang J, Meltzer PS, Yu J- W, Kao F-T, Chen DJ, Cerosaletti KM, Fournier REK, Todd S, Lewis T, Leach RJ, Naylor SL, Weissenbach J, Mecklin J-P, Jarvinen H, Petersen GM, Hamilton SR, Green J, Jass J, Watson P, Lynch HT, Trent JM, de la Chapelle A, Kinzler KW, Vogelstein B. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75:1215-1225 (1993).
40. Papadopoulos N, Nicolaides NC, Wei Y-F, Ruben SM, Carter KC, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM, Adams MD, Venter JC, Hamilton SR, Petersen GM, Watson P, Lynch HT, Peltomäki P, Mecklin J-P, de la Chapelle A, Kinzler KW, Vogelstein B. Mutation of a mutL homolog in hereditary colon cancer. Science 263:1625-1628 (1994).
41. Fishel R, Lescoe MK, Rao MRS, Copeland MG, Jenkins NA, Garber J, Kane M, Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75:1027-1038 (1993).
42. Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabino C, Lipford J, Lindblom A, Tannergard P, Bollag RJ, Godwin AR, Ward DC, Nordenskjold M, Fishel R, Kolodner R, Liskay RM. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368:258-261 (1994).
43. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Nat Acad Sci USA 89:7491-7495 (1992).
44. Harris CC. Chemical and physical carcinogenesis: advances and perspectives for the 1990s. Cancer Res 51 (Suppl 18):5023s-5044s (1991).
45. Richeldi L, Sorrentino R, Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science 262:242-244 (1993).
46. Bigbee WL, Langlois RG, Swift M, Jensen RH. Evidence for an elevated frequency of in vivo somatic cell mutations in ataxia telangiectasia. Am J Hum Genet 44:402-408 (1989).
47. Langlois RG, Bigbee WL, Jensen RH, German J. Evidence for increased in vivo mutations and somatic recombination in Bloom's syndrome. Proc Nat Acad Sci USA 86:670-674 (1989).
48. Norris PG, Limb GA, Hamblin AS, Lehmann AR, Arlett CF, Cole J, Waugh APW, Hawk JLM. Immune function, mutant frequency, and cancer risk in the DNA repair defective genodermatoses xeroderma pigmentosum, Cockayne's syndrome, and trichothiodystrophy. J Invest Dermatol 94:94-100 (1990).
49. Cole J, Arlett CF, Norris PG, Stephens G, Waugh AP, Beare DM, Green MH. Elevated hprt mutant frequency in circulating T-lymphocytes of xeroderma pigmentosum patients. Mutat Res 273:171-178 (1992).
50. Collins A, Duthie S, Ross M. Micronutrients and oxidative stress in the aetiology of cancer. Prog Nutr Soc 53:67-75 (1994).
51. Aidoo A, Lyn-Cook LE, Lensing S, Wamer W. Ascorbic acid (vitamin C) modulates the mutagenic effects produced by an alkylating agent in vivo. Environ Mol Mutagen 24:220-228 (1994).
52. Branda RF, O'Neill JP, Sullivan LM, Albertini RJ. Factors influencing mutation at the hprt locus in T-lymphocytes: women treated for breast cancer. Cancer Res 51:6603-6607 (1991).
53. Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 316:1289-1294 (1987).
54. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families by ataxia-telangiectasia. N Engl J Med 325:1831-1836 (1991).
55. Parsons R, Li G-M, Longley M, Modrich P, Liu B, Berk T, Hamilton SR, Kinzler KW, Vogelstein B. Mismatch repair deficiency in phenotypically normal human cells. Science 268:738-740 (1995).
56. Anwar WA. Monitoring of human populations at risk by different cytogenetic end points. Environ Health Perspect 102(Suppl 4):131-134 (1994).
57. Evans HJ. Mutation cytogenetics: past, present, and future. Mutat Res 204:355-363 (1988).
58. Norppa H, Luomahaara S, Heikanen H, Roth S, Sorsa M, Renzi L, Lindholm C. Micronucleus assay in lymphocytes as a tool to biomonitor human exposure to aneuploidogens and clastogens. Environ Health Perspect 101(Suppl 3): 139-143 (1993).
59. Fenech M. The cytokinesis-block micronucleus technique and its application to genotoxicity studies in human populations. Environ Health Perspect 101(Suppl 3):101-107 (1993).
60. Evans HJ, Neary GJ, Williamson FS. The relative biological efficiency of single doses of fast neutrons and gamma rays on Vicia faba roots and the effects of oxygen. II. Chromosome damage: the production of micro nuclei. Int J Radiat Biol 1:216-229 (1959).
61. Heddle JA, Carrano AV. The DNA content of micronuclei induced in mouse bone marrow by X-irradiation: evidence that micronuclei arise from acentric chromosome fragments. Mutat Res 44:63-69 (1977).
62. Fenech M, Morley AA. Cytokinesis block micronucleus method in human lymphocytes: effect of in vivo ageing and low dose X-irradiation. Mutat Res 161:193-198 (1986).
63. Latt SA. Sister chromatid exchanges, indicies of human chromosome damage and repair: detection by fluorescence and induction by mitomycin C. Proc Natl Acad Sci USA 71:3162-3166 (1974).
64. Perry P, Wolff S. New Giemsa method for differential staining of sister chromatids. Nature 261:156-158 (1974).
65. Tucker JD, Auletta A, Cimino MC, Dearfield KL, Jacobson-Kram D, Tice RR, Carrano AV. Sister-chromatid exchange: second report of the Gene-Tox Program. Mutat Res 297:101-180 (1993).
66. Fairbairn DW, Olive PL, O'Neill KL. The comet assay: a comprehensive review. Mutat Res 339:37-59 (1995).
67. Ostling O, Johanson KJ. Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells. Biochem Biophys Res Commun 123:291-298 (1984).
68. Albertini RJ, Nicklas JA, Fuscoe JC, Skopek TR, Branda RF, O'Neill JP. In vivo mutations in human blood cells: biomarkers for molecular epidemiology. Environ Health Perspect 99:135-141 (1993).
69. Albertini RJ, Castle KL, Borcherding WR. T-cell cloning to detect the mutant 6- thioguanine-resistant lymphocytes present in human peripheral blood. Proc Nat Acad Sci USA 79:6617-6621 (1982).
70. O'Neill JP, McGinniss MJ, Berman JK, Sullivan LM, Nicklas JA, Albertini RJ. Refinement of a T-lymphocyte cloning assay to quantify the in vivo thioguanine- resistant mutant frequency in humans. Mutagenesis 2:87-94 (1987).
71. Finette BA, Sullivan LM, O'Neill JP, Nicklas JA, Vacek PM, Albertini RJ. Determination of HPRT mutant frequencies in T-lymphocytes from a healthy pediatric population: statistical comparison between newborn, children and adult mutant frequencies, cloning efficiency and age. Mutat Res 308:223-231 (1994).
72. Langlois RG, Bigbee WL, Jensen RH. Measurements of the frequency of human erythrocytes with gene expression loss phenotypes in the glycophorin A locus. Hum Genet 74:353-362 (1987).
73. Grant S, Bigbee WL. In vivo somatic mutation and segregation at the human glycophorin A (GPA) locus. Mutat Res 288:163-172 (1993).
74. Cariello NF, Skopek TR. Analysis of mutation occurring at the human hprt locus. J Mol Biol 231:41-57 (1993).
75. Janatipour M, Trainor KJ, Kudaca R, Bennett G, Hay J, Turner DR, Morley AA. Mutations in human lymphocytes studied by an HLA selection system. Mutat Res 198:221-226 (1988).
76. Turner DR, Grist SA, Janatipour M, Morley AA. Mutations in human lymphocytes commonly involve gene duplication and resemble those seen in cancer cells. Proc Nat Acad Sci USA 85:3189-3193 (1988).
77. Grist SA, McCarron M, Kutlaca A, Turner DR, Morley AA. In vivo human somatic mutation: frequency and spectrum with age. Mutat Res 266:189-196 (1992).
78. Rainville IR, Albertini RJ, Nicklas JA. Breakpoints and junctional regions of intragenic deletions in the hprt gene in human T-cells. Som Cell Mol Genet 21:309-326 (1995).
79. Fuscoe JC, Zimmerman LJ, Lippert ML, Nicklas JA, O'Neill JP, Albertini RJ. V(D)J recombinase-like activity mediates hprt gene deletion in human fetal T-lymphocytes. Cancer Res 51:6001-6005 (1991).
80. Breit TM, Mol EJ, Wolvers-Tettero ILM, Ludwig W-D, van Wering ER, Van Dongen JJM. Site-specified deletions involving the tal-1 and sil genes are restricted to cells of the T-cell receptor α/β lineage: T cell receptor δ gene deletion mechanism affects multiple genes. J Exp Med 177:965-977 (1993).
81. Boehm T, Rabbitts TH. The human T cell receptor genes are targets for chromosomal abnormalities in T cell tumors. FASEB J 3:2344-2359 (1989).
82. Brown L, Cheng J-T, Chen Q, Siciliano MJ, Crist W, Buchanan G, Baer R. Site-specific recombination of the tal-1 gene is a common occurrence in human T cell leukemia. EMBO J 9:3343-3351 (1990).
83. Hagmar L, Br∮gger A, Hansteen I-L, Heim S, Högstedt B, Knudsen L, Lambert B, Linnainmaa K, Mitelman F, Nordenson I, Reuterwall C, Salomaa S, Skerfving S, Sorsa M. Cancer risks in humans predicted by increased levels of chromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. Cancer Res 54:2919-2922 (1994).
84. Bonassi S, Abbondandolo A, Camurri L, Dal Prá L, De Ferrari M, Degrassi F, Forni A, Lamberti L, Lando C, Padovani P, Sbrana I, Vecchio D, Puntoni R. Are chromosome aberrations in circulating lymphocytes predictive of future cancer onset in humans? Preliminary results of an Italian cohort study. Cancer Genet Cytogenet 79:133-135 (1995).
85. Kleinerman RA, Littlefield LG, Tarone RE, Sayer AM, Cookfair DL, Wactawski-Wende J, Inskip PD, Block A, Ramesh KH, Boice JD Jr. Chromosome aberrations in lymphocytes from women irradiated for benign and malignant gynecological disease. Radiat Res 139:40-46 (1994).